Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook
May 12, 2015 11:14 AM EDT
Leerink Partners maintains an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $40.00 (from $36.00), following the release on the 1Q15 results. Diplomat reported an adjusted EPS of $0.09 (+57% y/y), which was $0.01 ahead of Leerink estimates and consensus. Total revenue of $625M increased +34% y/y. Revenue was slightly ahead of Leerink estimate
but below consensus.
Leerink analyst, David Larsen, commented on the... More
May 12, 2015 8:03 AM EDT
Credit Suisse analyst G. Santangelo raised its price target on Outperform-rated Diplomat Pharmacy (NYSE: DPLO) to $40.00 (from $37.00) following Q1 'beat and raise'.
For an analyst ratings summary and ratings history on Diplomat Pharmacy... More
